ÂÜÀòÂÒÂ×

Modestus Obochi, PhD MBA, currently serves as Chief Business Officer at Sernova Corp. and advisor at 2Flo Ventures, LLC, where involvement includes board positions at several portfolio companies. Obochi is also a board member at Temprian Therapeutics and has held significant roles at Phlow Corporation, TKC Alliance, LLC, Accel-Rx, Coeptis Therapeutics, Pfenex Inc., Baxter International Inc., and Pfizer, contributing expertise in strategy, business development, and corporate governance. Academic qualifications include a PhD in Immunology from The University of British Columbia, an MBA in Strategic Management from Simon Fraser University, an M.Sc. in Nuclear Medicine & Radiobiology from Université de Sherbrooke, and a B.Sc. in Biochemistry & Microbiology from the University of Nigeria, Nsukka.